The pharmacokinetics, safety, and initial virologic response of a triple-protease inhibitor salvage regimen containing amprenavir, saquinavir, and ritonavir

Journal of Acquired Immune Deficiency Syndromes

Volumn 36, Issue 4, 2004, Pages 921-928

  Corbett, Amanda H ^a   Eron, Joseph J ^a   Fiscus, Susan A ^a   Rezk, Naser L ^a   Kashuba, Angela D M ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Amprenavir; Ritonavir; Saquinavir

Indexed keywords

AMPRENAVIR; DELAVIRDINE; EFAVIRENZ; INDINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; VIRUS RNA;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG SAFETY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LIVER TOXICITY; LOW DRUG DOSE; LYMPHOCYTE COUNT; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SALVAGE THERAPY; VIROLOGY;

ADULT; CARBAMATES; CD4 LYMPHOCYTE COUNT; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MIDDLE AGED; RITONAVIR; SALVAGE THERAPY; SAQUINAVIR; SULFONAMIDES; VIRAL LOAD;

EID: 3242667066     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200408010-00005     Document Type: Article

References (34)

1. th Conference on Retroviruses and Opportunistic Infections; February 2002; Seattle. Poster 423-W.
2. nd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 2002; San Diego. Poster A-1822.
3. rd International Workshop on Clinical Pharmacology of HIV Therapy; April 2002; Washington, DC. Poster 7.6.
4. Raguin G, Taburet AM, Chene G, et al. Pharmacokinetic (pk) parameters and virological response to the combination of lopinavir/ritonavir (LPV/r) and amprenavir (APV) in HIV infected patients with multiple treatment failures: week 6 results of Puzzle I - ANRS 104 study. Paper presented at: 9th Conference on Retroviruses and Opportunistic Infections; February 2002; Seattle. Poster G73e.
5. Reynolds HE, Gibbons SE, Tija JF, et al. The pharmacokinetic interaction of lopinavir/ritonavir and amprenavir in clinical practice. Paper presented at: XIV International AIDS Conference; July 7-12, 2002; Barcelona, Spain. Poster TuPeB4560.
6. Ribera E, Diaz M, Pou L, et al. Steady-state pharmacokinetics of double boosting regimen of lopinavir, plus minidose ritonavir, plus saquinavir soft-gel in HIV-infected adults. Paper presented at: XIV International AIDS Conference; July 7-12, 2002; Barcelona, Spain. Poster TuPeB4545.
7. Vanig T, Garg V, Brill M. Decreased plasma concentrations of amprenavir and lopinavir in HIV patients on this combination. Paper presented at: XIV International AIDS Conference; July 7-12, 2002; Barcelona, Spain. Poster MoPpB2009.
8. nd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 2002; San Diego. Poster #A-1823.
9. th Conference on Retroviruses and Opportunistic Infections; February 2002; Seattle. Poster 451-W.
10. th Conference on Retroviruses and Opportunistic Infections; February 2002; Seattle. Poster 421-W.
11. Zala C, Patterson P, Coll P, et al. Virological response and safety at 48 weeks of double boosted protease inhibitors with lopinavir/ritonavir plus either saquinavir or amprenavir in heavily pretreated HIV infected patients. Paper presented at: XIV International AIDS Conference; July 7-12, 2002; Barcelona, Spain. Poster TuPeB4492.
12. th Conference on Retroviruses and Opportunistic Infections; February 2002; Seattle. Poster #470-M.
13. th Conference on Retroviruses and Opportunistic Infections; February 2002; Seattle WA. Poster 440W.
14. th Infectious Diseases Society of America; October 24-27, 2002; Chicago. Poster 446.
15. rd International Workshop on Salvage Therapy for HIV Infection; April 12-14, 2000; Chicago. Poster 16.
16. St. Clair MH, Millard J, Rooney J, et al. In vitro antiviral activity of 141W94 (VX-478) in combination with other antiretroviral agents. Antiviral Res. 1996;29:53-56.
17. Kurowski M, Sternfeld T, Hill A, et al. Comparative pharmacokinetics and short-term safety of Fortovase®/ritonavir and Invirase®/ritonavir 1000mg/100mg BID. Paper presented at: 9th Conference on Retroviruses and Opportunistic infections; February 24-28, 2002; Seattle. Poster S29e.
18. Veldkamp AI, van Heeswijk TPG, Mulder JW, et al. Steady-state pharmacokinetics of twice-daily dosing of saquinavir plus ritonavir in HIV-1-infected individuals. J Acquir Immune Defic Syndr. 2001;27:344-349.
19. van Heeswijk RPG, Hoetelmans RMW, Harms R, et al. Simultaneous quantitative determination of the HIV protease inhibitors amprenavir, indinavir, ritonavir and saquinavir in human plasma by ion-pair high-performance liquid chromatography with ultraviolet detection. J Chromatogr. 1998;719:159-168.
20. National Institutes of Health, Division of AIDS. Table for grading severity of adult adverse experiences. Available at: http://aactg.s-3.com/ members/adulttox.htm. August 1992.
21. th Conference on Retroviruses and Opportunistic Infections; February 4-8, 2001; Chicago. Poster 332.
22. th International Congress on Drug Therapy in HIV Infections; October 22-26, 2000; Glasgow, UK. Poster 560.
23. Huang L, Wring SA, Woolley JL, et al. Induction of p-glycoprotein and cytochrome P450 3A by HIV protease inhibitors. Drug Metab Dispos. 2001;29:754-760.
24. th Conference on Retroviruses and Opportunistic Infections; February 24-28, 2002; Seattle. Poster 442W.
25. Tran JQ, Petersen C, Garrett M, et al. Pharmacokinetic interaction between amprenavir and delavirdine: evidence of induced clearance by amprenavir. Clin Pharmacol Ther. 2002;72:615-626.
26. Eagling VA, Wiltshire H, Whitcombe IW, et al. CYP3A4-mediated hepatic metabolism of the HIV-1 protease inhibitor saquinavir in vitro. Xenobiotica. 2002;32:1-17.
27. Kumar GN, Rodrigues AD, Buko AM, et al. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. Clin Pharmacokinet. 1996;277:423-431.
28. Kilby JM, Sfakianos G, Gizzi N, et al. Safety and pharmacokinetics of once-daily regimens of soft-gel capsule saquinavir plus minidose ritonavir in human immunodeficiency virus-negative adults. Antimicrob Agents Chemother. 2000;44:2672-2679.
29. Flaherty J, Kearney B, Wolf J, et al. Coadministration of tenofovir DF (TDF) and didanosine (ddI): a pharmacokinetic and safety evaluation. Paper presented at: 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; December 16-19, 2001; Chicago. Abstract I-1729.
30. th Conference on Retroviruses and Opportunistic Infections; February 10-14, 2003; Boston. Poster 533.
31. rd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 14-17, 2003; Chicago. Poster A-1616.
32. rd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 14-17, 2003; Chicago. Poster A-1617.
33. rd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 14-17, 2003; Chicago. Poster A-1615.
34. th Conference on Retroviruses and Opportunistic Infections; February 8-11, 2004; San Francisco. Poster 608.